Raymond James Financial Inc. Purchases New Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Raymond James Financial Inc. acquired a new stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor acquired 173,890 shares of the company’s stock, valued at approximately $71,893,000. Raymond James Financial Inc. owned 0.21% of IDEXX Laboratories at the end of the most recent quarter.

Several other large investors also recently modified their holdings of IDXX. Concurrent Investment Advisors LLC grew its stake in shares of IDEXX Laboratories by 4.7% in the 3rd quarter. Concurrent Investment Advisors LLC now owns 630 shares of the company’s stock valued at $318,000 after purchasing an additional 28 shares during the period. CWA Asset Management Group LLC bought a new stake in shares of IDEXX Laboratories in the 3rd quarter valued at approximately $308,000. Assetmark Inc. grew its stake in shares of IDEXX Laboratories by 4.1% in the 3rd quarter. Assetmark Inc. now owns 18,427 shares of the company’s stock valued at $9,310,000 after purchasing an additional 723 shares during the period. Sigma Planning Corp grew its stake in shares of IDEXX Laboratories by 12.6% in the 3rd quarter. Sigma Planning Corp now owns 1,892 shares of the company’s stock valued at $956,000 after purchasing an additional 212 shares during the period. Finally, HTG Investment Advisors Inc. bought a new stake in shares of IDEXX Laboratories in the 3rd quarter valued at approximately $204,000. 87.84% of the stock is currently owned by institutional investors.

IDEXX Laboratories Stock Up 0.3 %

NASDAQ:IDXX opened at $430.12 on Monday. The stock’s fifty day moving average price is $437.37 and its two-hundred day moving average price is $449.09. IDEXX Laboratories, Inc. has a 52-week low of $398.50 and a 52-week high of $562.25. The company has a debt-to-equity ratio of 0.28, a quick ratio of 0.95 and a current ratio of 1.31. The company has a market cap of $34.98 billion, a price-to-earnings ratio of 40.31, a P/E/G ratio of 3.41 and a beta of 1.39.

Wall Street Analysts Forecast Growth

IDXX has been the topic of several recent analyst reports. Morgan Stanley reduced their target price on IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating on the stock in a report on Wednesday, January 29th. StockNews.com downgraded IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Friday. Bank of America boosted their target price on IDEXX Laboratories from $475.00 to $535.00 and gave the stock a “neutral” rating in a report on Tuesday, February 4th. Piper Sandler boosted their target price on IDEXX Laboratories from $435.00 to $510.00 and gave the stock a “neutral” rating in a report on Monday, February 10th. Finally, Barclays boosted their target price on IDEXX Laboratories from $481.00 to $520.00 and gave the stock an “overweight” rating in a report on Tuesday, February 4th. Four analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, IDEXX Laboratories currently has a consensus rating of “Moderate Buy” and an average price target of $533.75.

Insiders Place Their Bets

In other news, Director M Anne Szostak sold 3,000 shares of the stock in a transaction on Friday, February 7th. The stock was sold at an average price of $465.94, for a total value of $1,397,820.00. Following the transaction, the director now owns 3,061 shares of the company’s stock, valued at $1,426,242.34. This represents a 49.50 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP George Fennell sold 9,986 shares of the stock in a transaction on Monday, February 10th. The shares were sold at an average price of $462.53, for a total value of $4,618,824.58. Following the completion of the transaction, the executive vice president now directly owns 8,176 shares in the company, valued at approximately $3,781,645.28. This trade represents a 54.98 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 2.11% of the company’s stock.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.